Rigel Pharmaceuticals (RIGL) Unusual Options Activity Today

Checking RIGL unusual options activity helps you spot when traders are making outsized bets on Rigel Pharmaceuticals before the broader market catches on. Rigel Pharmaceuticals's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor RIGL unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching RIGL unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking RIGL unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and RIGL unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases.

It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Catalysts rarely arrive without a footprint, and RIGL unusual options activity is often where that footprint shows up first. Our scanner tracks Rigel Pharmaceuticals's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at RIGL unusual options volume on the call side or chasing put sweeps, Rigel Pharmaceuticals's unusual options flow today is one click away, so put it on your radar before the headlines hit.